We just need approval and this will fly24 Jul 2025 08:23
The Prostate Screening EpiSwitch (PSE) test, a blood test that combines PSA (Prostate-Specific Antigen) with epigenetic analysis to improve prostate cancer detection, is being reviewed by NICE (National Institute for Health and Care Excellence). The test, developed by Oxford BioDynamics, aims to improve the accuracy of prostate cancer diagnosis, potentially reducing unnecessary biopsies and improving outcomes